Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

NCT04649359

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Beverly Hills Cancer Center Beverly Hills, California, United States
  • Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UCLA Hematology/Oncology Clinic Los Angeles, California, United States
  • UC Irvine Health - Chao Family Comprehensive Cancer Center Orange, California, United States
View all 40 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Chao Family Comprehensive Cancer Center Orange, California, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • Beth Israel Deaconess Medical Center (Bidmc) Boston, Massachusetts, United States
  • University of Michigan Health System Ann Arbor, Michigan, United States
View all 176 locations
View Trial Details
Active, Not Recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

NCT02213926

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Research Site Tampa, Florida, United States
  • Research Site Chicago, Illinois, United States
  • Research Site Niles, Illinois, United States
  • Research Site Peoria, Illinois, United States
View all 58 locations
View Trial Details
Active, Not Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

NCT04661007

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Aichi Cancer Center Hospital Aichi, Japan
  • Chiba Cancer Center Chiba, Japan
  • National Cancer Center Hospital East Chiba, Japan
  • University of Fukui Hospital Fukui, Japan
View all 23 locations
View Trial Details
Active, Not Recruiting

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)

NCT05354557

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Consent and Followup) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Consent and Follow-Up only) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Consent and Follow up) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk-Commack (Consent and Follow up) Commack, New York, United States
View Trial Details
Active, Not Recruiting

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

NCT02797470

Conditions
Blood-Borne Infections, Burkitt Lymphoma, Communicable Diseases, +41 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • UCSF Medical Center-Parnassus San Francisco, California, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Active, Not Recruiting

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Alaska Oncology and Hematology, LLC Anchorage, Alaska, United States
  • Arizona Oncology Associates, P.C. - HOPE Phoenix, Arizona, United States
  • UCLA Medical Center Los Angeles, California, United States
  • USO-Rocky Mountain Cancer Center Denver, Colorado, United States
View all 189 locations
View Trial Details

Related conditions